
    
      This is an investigator-initiated randomized non-comparative phase II trial consisting of 40
      patients with resectable stage III-IVa CSCC randomized 1:1 to ARM A: 2 courses of nivolumab 3
      mg/kg in week 0 and 2, or ARM B: 2 courses of nivolumab 3 mg/kg in week 0 and 2 plus 1 course
      of ipilimumab 1mg/kg in week 0. Both treatment arms are neo-adjuvant and applied prior to
      standard of care (consisting of surgery at week 4 with or without adjuvant radiotherapy).
    
  